10,000 eczema patients enrolled in landmark Long-Term safety study

NCT ID NCT04504955

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: CorEvitas Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This registry will follow 10,000 adults with atopic dermatitis (eczema) who are already using approved treatments. Researchers will collect data on how well the treatments work and any side effects over time. The goal is to better understand the disease, its complications, and current treatment practices in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this registry could provide real-world data on how well current treatments work and their long-term safety, helping doctors make better treatment decisions.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by factors like patient selection or reporting bias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Show contact details

Locations

CorEvitas, LLC

Waltham, Massachusetts, 02451, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.